Found 8 matching trials
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma PHASE2 This is a single-arm, open-label, multicenter Phase II clinical study desig...
Show More Location
Beijing Cancer Hospitial
Learn More & Join Trial
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma PHASE3 This is a randomized, double-blind, multi-center, phase III clinical trial ...
Show More Location
Beijing Friendship Hospital,Capital Medical University
Learn More & Join Trial
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) PHASE1 In this study, participants with different types of advanced solid tumors w...
Show More Location
Sun Yat-sen University Cancer Center (SYSUCC)
Learn More & Join Trial
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer PHASE1 In this phase Ib/II study, participants with metastatic castration-resistan...
Show More Location
Cancer Hosipital of Shandong First Medical University,440 Jiyan Road, Jinan City, Shandong Province
Learn More & Join Trial
Study of XNW5004 Tablets in Advanced Prostate Cancer PHASE2 Phase Ib A preliminary design of 2 cohorts is planned for this phase, with ...
Show More Location
Multiple Locations
Treatments Being Tested
XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, QDD XNW5004 800/1200 mg BID in Combination with Docetaxel plus Prednisone XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Enzalutamide 160 mg, PO, QD. Each treatment cycle consists of 4 weeks. Subsequent development plans will be determined based on preliminary study results. Learn More & Join Trial
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors PHASE1 Patients with advanced tumors diagnosed histologically or cytologically at ...
Show More Location
Hematology Hospital, Chinese Academy of Medical Sciences
Learn More & Join Trial
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma PHASE1 In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used fo...
Show More Location
Shanghai Cancer Center
Learn More & Join Trial
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma PHASE2 This is an open-label, multi-center clinical study to evaluate the efficacy...
Show More Location
Multiple Locations
Learn More & Join Trial